115 related articles for article (PubMed ID: 19300322)
21. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
22. Cytologic diagnosis of atypical squamous cells of undetermined significance in perimenopausal and postmenopausal women: lessons learned from human Papillomavirus DNA testing.
Johnston EI; Logani S
Cancer; 2007 Jun; 111(3):160-5. PubMed ID: 17506090
[TBL] [Abstract][Full Text] [Related]
23. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient groups.
Yeoh GP; Tse MP; Chan KW; Lord L
Acta Cytol; 2006; 50(6):627-31. PubMed ID: 17152273
[TBL] [Abstract][Full Text] [Related]
25. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
26. Trends of human papillomavirus testing in cervical cancer screening at a large academic cytology laboratory.
Phelan DF; Boitnott JK; Clark DP; Dubay LC; Gravitt PE
Obstet Gynecol; 2011 Aug; 118(2 Pt 1):289-295. PubMed ID: 21775844
[TBL] [Abstract][Full Text] [Related]
27. Impact of Screening Modality on the Detection of Cervical Adenocarcinoma In Situ and Adenocarcinoma.
Zhang RC; Vue NC; Obasi LU; Vogel RI; Subramanian AT; Khalifa MA; Reddy BR; Erickson BK
J Low Genit Tract Dis; 2021 Oct; 25(4):267-269. PubMed ID: 34265818
[TBL] [Abstract][Full Text] [Related]
28. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up.
Thrall MJ; Russell DK; Facik MS; Yao JL; Warner JN; Bonfiglio TA; Giampoli EJ
Am J Clin Pathol; 2010 Jun; 133(6):894-8. PubMed ID: 20472847
[TBL] [Abstract][Full Text] [Related]
29. Common abnormal results of pap and human papillomavirus cotesting: what physicians are recommending for management.
Berkowitz Z; Saraiya M; Benard V; Yabroff KR
Obstet Gynecol; 2010 Dec; 116(6):1332-1340. PubMed ID: 21099599
[TBL] [Abstract][Full Text] [Related]
30. Factors Associated With Guideline-concordant and Excessive Cervical Cancer Screening: A Mixed Methods Study.
Perkins RB; Fuzzell L; Lake P; Brownstein NC; Fontenot HB; Michel A; Whitmer A; Vadaparampil ST
Womens Health Issues; 2024; 34(3):257-267. PubMed ID: 38383228
[TBL] [Abstract][Full Text] [Related]
31. Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems.
Kruse GR; Lykken JM; Kim EJ; Haas JS; Higashi RT; Atlas SJ; McCarthy AM; Tiro JA; Silver MI; Skinner CS; Kamineni A
JNCI Cancer Spectr; 2023 Jan; 7(1):. PubMed ID: 36469348
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.
Ronco G; Dillner J; Elfström KM; Tunesi S; Snijders PJ; Arbyn M; Kitchener H; Segnan N; Gilham C; Giorgi-Rossi P; Berkhof J; Peto J; Meijer CJ;
Lancet; 2014 Feb; 383(9916):524-32. PubMed ID: 24192252
[TBL] [Abstract][Full Text] [Related]
33. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.
Dinkelspiel H; Fetterman B; Poitras N; Kinney W; Cox JT; Lorey T; Castle PE
J Low Genit Tract Dis; 2014 Jan; 18(1):57-60. PubMed ID: 24022057
[TBL] [Abstract][Full Text] [Related]
34. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
35. Clinical implementation of a cervical cancer screening program via co-testing at a university hospital.
Denninghoff V; von Petery F; Fresno C; Galarza M; Torres F; Avagnina A; Fishkel V; Krupitzki H; Fiorillo A; Monge F
PLoS One; 2022; 17(12):e0278476. PubMed ID: 36454784
[TBL] [Abstract][Full Text] [Related]
36. Harmless or Threatening? Interpreting the Results of Molecular Diagnosis in the Context of Virus-Host Relationships.
Abade Dos Santos FA; Portela SJ; Nogueira T; Carvalho CL; de Sousa R; Duarte MD
Front Microbiol; 2021; 12():647730. PubMed ID: 34093464
[TBL] [Abstract][Full Text] [Related]
37. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial.
Winer RL; Lin J; Tiro JA; Miglioretti DL; Beatty T; Gao H; Kimbel K; Thayer C; Buist DSM
JAMA Netw Open; 2019 Nov; 2(11):e1914729. PubMed ID: 31693128
[TBL] [Abstract][Full Text] [Related]
38. Application of p16/Ki-67 dual-staining cytology in cervical cancers.
Yu L; Fei L; Liu X; Pi X; Wang L; Chen S
J Cancer; 2019; 10(12):2654-2660. PubMed ID: 31258773
[TBL] [Abstract][Full Text] [Related]
39. FLEXIBLE RISK PREDICTION MODELS FOR LEFT OR INTERVAL-CENSORED DATA FROM ELECTRONIC HEALTH RECORDS.
Hyun N; Cheung LC; Pan Q; Schiffman M; Katki HA
Ann Appl Stat; 2017 Jun; 11(2):1063-1084. PubMed ID: 31223347
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
